SCHEMBL4157513

SCHEMBL4157513

CCCNS(=O)(=O)c1ccccc1C=C1c2ccccc2CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.45
CA9 Q16790 3/20 0.45
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
NR3C2 P08235 1/20 0.42
AR P10275 1/20 0.42
SLC6A2 P23975 3/20 0.41
HTR2C P28335 3/20 0.41
HTR2B P41595 3/20 0.41
LMNA P02545 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 2/20 0.41
ADRB2 P07550 2/20 0.41
RET P07949 2/20 0.41
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
ADRB1 P08588 2/20 0.41
HTR1A P08908 2/20 0.41
CHRM5 P08912 2/20 0.41
ADRA2A P08913 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159221 0.87 NR3C1 (0.41) CA12CA9NR3C1PGRNR3C2
SCHEMBL4164335 0.87 POLB (0.43) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4170930 0.83 NR3C2 (0.46) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4175519 0.82 NR3C1 (0.39) CA12CA9NR3C1PGRNR3C2
SCHEMBL4165313 0.77 NR3C1 (0.42) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4172411 0.76 MIF (0.46) CA12CA9NR3C1PGRNR3C2
SCHEMBL4164510 0.76 NR3C1 (0.46) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4170326 0.76 NR3C2 (0.43) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4155389 0.75 ALDH1A1 (0.41) NR3C1PGRNR3C2ARSLC6A2
SCHEMBL4158940 0.75 ALDH1A1 (0.43) NR3C1PGRNR3C2ARSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 CA12 2912/4885CA9 3508/4885NR3C1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.